CO4990967A1 - Derivados de la dolastatina 15 - Google Patents

Derivados de la dolastatina 15

Info

Publication number: CO4990967A1
Authority: CO; Colombia
Prior art keywords: alkyl; hydrogen; substituted; fls2or; formula
Prior art date: 1997-07-18

Application number

CO98040961A

Other languages

English (en)

Spanish (es)

Inventor

Bernd Janssen

Teresa Barlozzari

Andreas Haupt

Thomas Zierke

Andreas Kling

Original Assignee

Abbott Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-18

Filing date

1998-07-17

Publication date

2000-12-26

1998-07-17 Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg

2000-12-26 Publication of CO4990967A1 publication Critical patent/CO4990967A1/es

Links

AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical class CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 title 1
229910052739 hydrogen Inorganic materials 0.000 abstract 39
239000001257 hydrogen Substances 0.000 abstract 39
125000000217 alkyl group Chemical group 0.000 abstract 32
150000002431 hydrogen Chemical class 0.000 abstract 22
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 14
-1 norvalyl Chemical group 0.000 abstract 9
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 abstract 4
150000001413 amino acids Chemical class 0.000 abstract 4
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
239000002253 acid Substances 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 3
150000002222 fluorine compounds Chemical group 0.000 abstract 3
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 abstract 3
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 abstract 2
125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
125000000547 substituted alkyl group Chemical group 0.000 abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 abstract 1
125000001203 alloisoleucine group Chemical group 0.000 abstract 1
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 1
125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 abstract 1
229950003188 isovaleryl diethylamide Drugs 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003147 proline derivatives Chemical class 0.000 abstract 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

CO98040961A 1997-07-18 1998-07-17 Derivados de la dolastatina 15 CO4990967A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/896,394 US6143721A (en)	1997-07-18	1997-07-18	Dolastatin 15 derivatives

Publications (1)

Publication Number	Publication Date
CO4990967A1 true CO4990967A1 (es)	2000-12-26

Family

ID=25406130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CO98040961A CO4990967A1 (es)	1997-07-18	1998-07-17	Derivados de la dolastatina 15

Country Status (33)

Country	Link
US (6)	US6143721A (fr)
EP (1)	EP0991658B1 (fr)
JP (4)	JP4508413B2 (fr)
KR (1)	KR100579748B1 (fr)
CN (1)	CN1268636C (fr)
AR (1)	AR018501A1 (fr)
AT (1)	ATE314387T1 (fr)
AU (1)	AU750120B2 (fr)
BG (1)	BG65212B1 (fr)
BR (1)	BR9810911A (fr)
CA (1)	CA2296036C (fr)
CO (1)	CO4990967A1 (fr)
CY (1)	CY1107047T1 (fr)
CZ (1)	CZ303045B6 (fr)
DE (1)	DE69832982T2 (fr)
DK (1)	DK0991658T3 (fr)
ES (1)	ES2258819T3 (fr)
HK (1)	HK1029125A1 (fr)
HR (1)	HRP980397A2 (fr)
HU (1)	HU228996B1 (fr)
ID (1)	ID24669A (fr)
IL (1)	IL133784A (fr)
MY (1)	MY135057A (fr)
NO (1)	NO326827B1 (fr)
NZ (1)	NZ502296A (fr)
PL (1)	PL197884B1 (fr)
PT (1)	PT991658E (fr)
RU (1)	RU2195462C2 (fr)
SK (1)	SK286581B6 (fr)
TR (2)	TR200000132T2 (fr)
TW (1)	TW533217B (fr)
WO (1)	WO1999003879A1 (fr)
ZA (1)	ZA986358B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010009901A1 (en)	1996-12-11	2001-07-26	Basf Aktiengesellschaft Germany	Antineoplastic peptides
US6143721A (en) *	1997-07-18	2000-11-07	Basf Aktiengesellschaft	Dolastatin 15 derivatives
AU2001227375A1 (en)	2000-02-08	2001-08-20	Herbert T. Nagasawa	N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) *	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US7256257B2 (en) *	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
CA2479764C (fr) *	2002-03-22	2013-07-30	Eisai Co., Ltd.	Derives de l'hemiasterline et leurs utilisations
US7064211B2 (en) *	2002-03-22	2006-06-20	Eisai Co., Ltd.	Hemiasterlin derivatives and uses thereof
EP1545613B9 (fr) *	2002-07-31	2012-01-25	Seattle Genetics, Inc.	Conjugues d'auristatine et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
SG195524A1 (en)	2003-11-06	2013-12-30	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
WO2006063135A2 (fr) *	2004-12-09	2006-06-15	Eisai R & D Management Co., Ltd.	Criblage d'isotype de tubuline en therapie du cancer, au moyen d'analogues d'hemiasterline
JP4954983B2 (ja)	2005-05-18	2012-06-20	ファーマサイエンス・インコーポレイテッド	Ｂｉｒドメイン結合化合物
AU2007250443B2 (en)	2006-05-16	2013-06-13	Pharmascience Inc.	IAP BIR domain binding compounds
ES2528922T3 (es)	2007-07-16	2015-02-13	Genentech, Inc.	Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
ES2579323T3 (es)	2007-07-16	2016-08-09	Genentech, Inc.	Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
DE102007039706A1 (de)	2007-08-22	2009-02-26	Erhard Prof. Dr.-Ing. Kohn	Chemischer Sensor auf Diamantschichten
AR070168A1 (es)	2008-01-31	2010-03-17	Genentech Inc	Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
AR079528A1 (es)	2009-12-18	2012-02-01	Idenix Pharmaceuticals Inc	Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
RU2573994C2 (ru)	2010-02-10	2016-01-27	Иммьюноджен, Инк	Антитела против cd20 и их применение
SG10201501095WA (en)	2010-02-12	2015-04-29	Pharmascience Inc	Iap bir domain binding compounds
JP6133431B2 (ja)	2012-11-24	2017-05-24	ハンジョウディーエーシーバイオテックシーオー．，エルティディ．ＨａｎｇｚｈｏｕＤａｃＢｉｏｔｅｃｈＣｏ．，Ｌｔｄ．	親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
JP6417421B2 (ja)	2014-02-28	2018-11-07	ハンジョウディーエーシーバイオテックシーオー．，エルティディ．ＨａｎｇｚｈｏｕＤａｃＢｉｏｔｅｃｈＣｏ．，Ｌｔｄ．	荷電連結体及び共役体のためのその使用
BR112017023576A2 (pt)	2014-09-23	2023-10-03	Genentech Inc	Método para tratar uma disfunção proliferativa de células b
CN113350518A (zh)	2015-07-12	2021-09-07	杭州多禧生物科技有限公司	与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220150408A (ko)	2016-11-14	2022-11-10	항저우 디에이씨 바이오테크 씨오, 엘티디	결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
EP4400121A1 (fr)	2021-09-03	2024-07-17	Toray Industries, Inc.	Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP4426727A2 (fr)	2021-11-03	2024-09-11	Hangzhou Dac Biotech Co., Ltd.	Conjugaison spécifique d'un anticorps

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816444A (en) *	1987-07-10	1989-03-28	Arizona Board Of Regents, Arizona State University	Cell growth inhibitory substance
US4879278A (en) *	1989-05-16	1989-11-07	Arizona Board Of Regents	Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
SG87056A1 (en) *	1991-08-09	2002-03-19	Teikoku Hormone Mfg Co Ltd	Novel tetrapeptide derivative
WO1993017388A1 (fr) *	1992-02-26	1993-09-02	Clark Paul C	Systeme de protection d'ordinateurs a l'aide de jetons intelligents ou de cartes a memoire
US5533097A (en) *	1992-02-26	1996-07-02	Motorola, Inc.	Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
US5831002A (en) *	1992-05-20	1998-11-03	Basf Aktiengesellschaft	Antitumor peptides
CA2136339C (fr) *	1992-05-20	2008-02-05	Andreas Haupt	Derives de la dolastatine
ATE196296T1 (de) *	1992-12-16	2000-09-15	Basf Ag	Dolastatin analog
US5554993A (en) *	1994-01-04	1996-09-10	Panasonic Technologies, Inc.	Global position determining system and method
US5530097A (en) *	1994-08-01	1996-06-25	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory peptide amides
US5504191A (en) *	1994-08-01	1996-04-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) *	1994-09-14	1996-09-10	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Synthesis of dolastatin 15
US5663149A (en) *	1994-12-13	1997-09-02	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) *	1995-03-23	1997-04-08	Martin; John R.	Dual mode gaming device methods and systems
US5970143A (en) *	1995-11-22	1999-10-19	Walker Asset Management Lp	Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) *	1995-11-09	1998-09-15	Basf Aktienegesellschaft	Oligopeptides, the preparation and use thereof
TW474946B (en) *	1995-12-15	2002-02-01	Basf Ag	Novel compounds, the preparation and use thereof
US6104815A (en) *	1997-01-10	2000-08-15	Silicon Gaming, Inc.	Method and apparatus using geographical position and universal time determination means to provide authenticated, secure, on-line communication between remote gaming locations
US6143721A (en) *	1997-07-18	2000-11-07	Basf Aktiengesellschaft	Dolastatin 15 derivatives
US6554705B1 (en) *	1997-08-22	2003-04-29	Blake Cumbers	Passive biometric customer identification and tracking system
US6629591B1 (en) *	2001-01-12	2003-10-07	Igt	Smart token
US6438382B1 (en) *	2001-02-14	2002-08-20	Telefonaktiebolaget Lm Ericsson (Publ.)	Expedited location determination in analog service areas

1997
- 1997-07-18 US US08/896,394 patent/US6143721A/en not_active Expired - Lifetime
1998
- 1998-07-07 DK DK98935531T patent/DK0991658T3/da active
- 1998-07-07 JP JP2000503101A patent/JP4508413B2/ja not_active Expired - Fee Related
- 1998-07-07 NZ NZ502296A patent/NZ502296A/en not_active IP Right Cessation
- 1998-07-07 CZ CZ20000176A patent/CZ303045B6/cs not_active IP Right Cessation
- 1998-07-07 BR BR9810911-1A patent/BR9810911A/pt not_active Application Discontinuation
- 1998-07-07 WO PCT/US1998/013901 patent/WO1999003879A1/fr active IP Right Grant
- 1998-07-07 TR TR2000/00132T patent/TR200000132T2/xx unknown
- 1998-07-07 SK SK1879-99A patent/SK286581B6/sk not_active IP Right Cessation
- 1998-07-07 IL IL13378498A patent/IL133784A/xx not_active IP Right Cessation
- 1998-07-07 PT PT98935531T patent/PT991658E/pt unknown
- 1998-07-07 AT AT98935531T patent/ATE314387T1/de active
- 1998-07-07 TR TR2001/03545T patent/TR200103545T2/xx unknown
- 1998-07-07 ES ES98935531T patent/ES2258819T3/es not_active Expired - Lifetime
- 1998-07-07 CN CNB988073595A patent/CN1268636C/zh not_active Expired - Fee Related
- 1998-07-07 ID IDW20000322A patent/ID24669A/id unknown
- 1998-07-07 CA CA002296036A patent/CA2296036C/fr not_active Expired - Fee Related
- 1998-07-07 EP EP98935531A patent/EP0991658B1/fr not_active Expired - Lifetime
- 1998-07-07 KR KR1020007000565A patent/KR100579748B1/ko not_active Expired - Fee Related
- 1998-07-07 DE DE69832982T patent/DE69832982T2/de not_active Expired - Lifetime
- 1998-07-07 AU AU84758/98A patent/AU750120B2/en not_active Ceased
- 1998-07-07 HU HU0004234A patent/HU228996B1/hu not_active IP Right Cessation
- 1998-07-07 RU RU2000103960/04A patent/RU2195462C2/ru not_active IP Right Cessation
- 1998-07-07 PL PL338144A patent/PL197884B1/pl unknown
- 1998-07-15 AR ARP980103445A patent/AR018501A1/es active IP Right Grant
- 1998-07-16 HR HR08/896,394A patent/HRP980397A2/hr not_active Application Discontinuation
- 1998-07-17 CO CO98040961A patent/CO4990967A1/es unknown
- 1998-07-17 ZA ZA9806358A patent/ZA986358B/xx unknown
- 1998-07-18 TW TW087111729A patent/TW533217B/zh active
- 1998-07-18 MY MYPI98003298A patent/MY135057A/en unknown
2000
- 2000-01-17 NO NO20000231A patent/NO326827B1/no not_active IP Right Cessation
- 2000-01-17 BG BG104089A patent/BG65212B1/bg unknown
- 2000-07-18 US US09/618,694 patent/US6458765B1/en not_active Expired - Lifetime
- 2000-12-28 HK HK00108461A patent/HK1029125A1/xx not_active IP Right Cessation
2002
- 2002-09-25 US US10/255,118 patent/US7084110B2/en not_active Expired - Lifetime
2006
- 2006-03-13 CY CY20061100348T patent/CY1107047T1/el unknown
- 2006-04-18 US US11/406,512 patent/US7662786B2/en not_active Expired - Fee Related
2008
- 2008-12-11 JP JP2008315269A patent/JP5047935B2/ja not_active Expired - Fee Related
- 2008-12-11 JP JP2008315263A patent/JP5122429B2/ja not_active Expired - Fee Related
2009
- 2009-12-29 US US12/648,446 patent/US8163698B2/en not_active Expired - Fee Related
2012
- 2012-04-16 US US13/447,529 patent/US20130046077A1/en not_active Abandoned
- 2012-06-20 JP JP2012138485A patent/JP2012211164A/ja active Pending

Also Published As

Publication number	Publication date
CN1268636C (zh)	2006-08-09
US6143721A (en)	2000-11-07
BR9810911A (pt)	2000-08-01
US7662786B2 (en)	2010-02-16
US8163698B2 (en)	2012-04-24
US20060270606A1 (en)	2006-11-30
CY1107047T1 (el)	2012-09-26
CZ2000176A3 (en)	2001-06-13
JP2001515010A (ja)	2001-09-18
HUP0004234A3 (en)	2001-08-28
NZ502296A (en)	2002-02-01
US20030153505A1 (en)	2003-08-14
TW533217B (en)	2003-05-21
CA2296036C (fr)	2007-05-01
DE69832982T2 (de)	2006-08-24
BG65212B1 (bg)	2007-07-31
CZ303045B6 (cs)	2012-03-07
NO326827B1 (no)	2009-02-23
US6458765B1 (en)	2002-10-01
IL133784A (en)	2005-09-25
IL133784A0 (en)	2001-04-30
WO1999003879A1 (fr)	1999-01-28
ES2258819T3 (es)	2006-09-01
NO20000231D0 (no)	2000-01-17
HU228996B1 (hu)	2013-07-29
US7084110B2 (en)	2006-08-01
SK187999A3 (en)	2000-09-12
PT991658E (pt)	2006-05-31
TR200103545T2 (tr)	2002-06-21
AU750120B2 (en)	2002-07-11
CN1264388A (zh)	2000-08-23
DE69832982D1 (de)	2006-02-02
ZA986358B (en)	2000-01-17
US20100099843A1 (en)	2010-04-22
JP5122429B2 (ja)	2013-01-16
MY135057A (en)	2008-01-31
CA2296036A1 (fr)	1999-01-28
KR100579748B1 (ko)	2006-05-15
EP0991658B1 (fr)	2005-12-28
TR200000132T2 (tr)	2000-05-22
JP2009137967A (ja)	2009-06-25
SK286581B6 (sk)	2009-01-07
RU2195462C2 (ru)	2002-12-27
KR20010021998A (ko)	2001-03-15
ATE314387T1 (de)	2006-01-15
JP4508413B2 (ja)	2010-07-21
DK0991658T3 (da)	2006-05-15
PL338144A1 (en)	2000-09-25
HK1029125A1 (en)	2001-03-23
NO20000231L (no)	2000-01-17
EP0991658A1 (fr)	2000-04-12
ID24669A (id)	2000-07-27
AU8475898A (en)	1999-02-10
HRP980397A2 (en)	1999-04-30
BG104089A (en)	2000-12-29
HUP0004234A2 (hu)	2001-05-28
JP2009137968A (ja)	2009-06-25
JP2012211164A (ja)	2012-11-01
US20130046077A1 (en)	2013-02-21
PL197884B1 (pl)	2008-05-30
JP5047935B2 (ja)	2012-10-10
AR018501A1 (es)	2001-11-28

Publication	Publication Date	Title
CO4990967A1 (es)	2000-12-26	Derivados de la dolastatina 15
ES2619332T3 (es)	2017-06-26	Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
BRPI0006823B8 (pt)	2021-05-25	composição farmacêutica estabilizada, preparação de injeção, e kit comercial
PE20220765A1 (es)	2022-05-16	Compuestos y metodos para el tratamiento de covid-19
WO2008007113A3 (fr)	2008-10-23	Combinaisons pharmaceutiques
BR9917080A (pt)	2002-03-12	Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
CO6210690A2 (es)	2010-10-20	Nuevos derivados de isoquinolina e isoquinolinona sustituidos
CO6260099A2 (es)	2011-03-22	Depsipeptidos ciclicos
AR065300A1 (es)	2009-05-27	Compuestos quimicos derivados de 1,2-pirazol
HUP0300850A2 (hu)	2003-07-28	Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
PE20000940A1 (es)	2000-10-06	Derivados de pirazol sustituido
AR048454A1 (es)	2006-04-26	Azaindoles utiles como inhibidores de las proteinas quinasas jak u otras proteinas quinasas
DE69932424D1 (de)	2006-08-31	Melanocortin 1 rezeptorselektive verbindungen
AR071387A1 (es)	2010-06-16	Pirimidin-5-carboxamidas sustituidas
PE20050370A1 (es)	2005-06-04	Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c
BRPI0619255B8 (pt)	2021-05-25	composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
NZ332220A (en)	2000-03-27	Inclusion complexes of aryl-piperazinyl-alkylene-heterocyclic salts (such as ziprasidone) and cyclodextrin
BRPI0414817A (pt)	2006-11-14	derivados de ácido indol substituìdos e seu uso como inibidores de pai-l
AR024364A1 (es)	2002-10-02	Una composicion cosmetica para el adelgazamiento a base l-arginina, de un analogo de l-arginina, o de uno de sus derivados, que se administra por viatopica
AR049333A1 (es)	2006-07-19	Azaindoles inhibidores de proteinquinasas rock y otras proteinas quinasas. composiciones farmaceuticas.
PE20040780A1 (es)	2005-01-14	Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
AR070791A1 (es)	2010-05-05	Derivados de imidazo[4, 5 - d]piridazina, una composicion farmaceutica que los comprende y su uso en el tratamiento de una infeccion viral mediada por el virus de la hepatitis c.
HUP0001796A2 (hu)	2000-11-28	Dipeptid-benzamidinek mint kininogenáz inhibitorok, és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0002330A2 (hu)	2001-06-28	Azetidinilpropilpiperidin-származékok, ezek intermedierjei és tachikinin antagonistaként történő alkalmazásuk
AR013815A1 (es)	2001-01-31	NUEVOS DERIVADOS DEL ACIDO 4-FORMIL-4, 4a, 5, 6, 7, 7a, 8, 8a-OCTAHIDRO- 7-METIL-3-(1-METILETIL)-1,4-METANO-S-INDACEN-3a(1H)-CARBOXILICO, UN PROCESOPARA SU PREPARACION, SU USO EN LA FABRICACION DE UN MEDICAMENTO Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE.